New hope for Tough-to-Treat lymphoma: mosunetuzumab under the microscope
NCT ID NCT07278921
First seen Jan 11, 2026 · Last updated May 07, 2026 · Updated 20 times
Summary
This study looks back at medical records of 25 adults with relapsed or refractory follicular lymphoma who received mosunetuzumab through a compassionate use program after at least two prior therapies. The goal is to measure how many patients respond to the drug, how long they stay cancer-free, and what side effects occur. The study does not test a new treatment but gathers real-world data to understand mosunetuzumab's effectiveness and safety in this hard-to-treat group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS Ospedale San Raffaele
RECRUITINGMilan, 20132, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.